treatment of high-risk PCI patients

Roundtable Discusses Protected PCI for High-Risk Patients

December 1, 2015

In the video below, Dr. John Lasala from Washington University, St. Louis, Missouri, hosts a roundtable discussion on Protected PCI with Dr. Bill Lombardi from the University of Washington, Seattle, Washington, Dr. Jeff Moses, Columbia University, New York, NY, and Dr. Bill O’Neill, Henry Ford Hospital, Detroit, Michigan.

Dr. Lasala begins with the FDA’s recognition and new indication that high-risk patients that are hemodynamically stable, but who are experiencing severe coronary artery disease and depressed left ventricular ejection fraction may benefit from the hemodynamic support provided by the Impella® 2.5 heart pump, when undergoing a percutaneous coronary intervention. The Impella® 2.5 heart pump is the first hemodynamic support device proven safe and effective for use during elective and urgent high-risk PCI.

Dr. Moses explains that high-risk patients are those with complex coronary artery disease who are hemodynamically stable, have left ventricular ejection fraction ≤35%, and comorbid conditions such as heart failure, peripheral vascular disease, complex lesions, diabetes, advanced age, and unstable angina.

Through a case study, Dr. Lombardi illustrates how the Impella 2.5 increases and maintains mean arterial pressure during the PCI procedure, allowing the cardiologist the time for a thorough procedure and complete revascularization of blood vessels, even if chronic total occlusions are present.

Complete revascularization is the therapeutic goal of the PCI procedure. The benefits of complete revascularization include, among other outcomes decreased major adverse cardiovascular and cerebrovascular events (MACCE), myocardial infarctions, and repeat revascularizations.

Dr. O’Neill reviews clinical outcomes from Protected PCI studies, specifically the PROTECT II study (O’Neill et al. 2012). When hemodynamic support with Impella was provided to allow for complete revascularization, these high-risk patients had reduced MACCE compared to IABP.

Clinically, patient outcomes improve left ventricular ejection fraction, provide symptom relief, and a better quality of life after the Protected PCI procedure. The Protected PCI procedure is cost-effective as indicated by shorter hospital stays and a decreased need for readmission for repeat procedures.

The participants discuss postgraduate education and fellowships for specific training to treat this high-risk group of patents and conduct Protected PCI procedures with hemodynamic support.

Listen to the details of this fascinating discussion on treating this high-risk group of patients with hemodynamic support to reduce their symptoms and improve their lives by watching the video above or by clicking here.

To learn more about the Impella® platform of heart pumps, including important risk and safety information associated with the use of the devices, please visit: